Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Assoc...
March 30 2017 - 8:30AM
Business Wire
- Plenary Presentation on Positive
Primary Analysis of the ZUMA-1 Pivotal CAR-T Trial in Patients with
Aggressive Non-Hodgkin Lymphoma
- Plenary and Oral Presentations
Highlighting Biomarkers and Product Characteristics Associated with
Adverse Events and Objective Response in Patients with Aggressive
Non-Hodgkin Lymphoma
- Oral and Poster Presentations on
Preclinical Development of KITE-585, an anti-BCMA CAR T-cell
Therapy Candidate, for Multiple Myeloma
Kite Pharma, Inc. (Nasdaq:KITE) today announced new data
presentations from multiple studies related to its lead
investigational candidate, axicabtagene ciloleucel, at the American
Association of Cancer Research (AACR) Annual Meeting in Washington
D.C., April 1-5, 2017. Kite will also present pre-clinical data
relating to KITE-585, the company’s fully human anti-B cell
maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
product candidate. The full text for clinical trial abstracts will
be available online March 31, 2017, at 4:30 p.m. Eastern Time,
through the AACR website at www.aacr.org.
“We are excited to present the primary analysis of ZUMA-1. The
results demonstrate the promise of anti-CD19 CAR T-cell therapy to
transform treatment of B-cell malignancies,” said David Chang,
M.D., Ph.D., Executive Vice President, Research and Development,
and Chief Medical Officer. “We intend to apply the learnings from
ZUMA-1, as well as our internal clinical development and
manufacturing expertise, to accelerate the development of some of
our most promising pipeline candidates such as KITE-585 into the
clinic later this year.”
Oral Presentations
Primary results from ZUMA-1: a pivotal trial of
axicabtagene ciloleucel (axicel; KTE-C19) in patients with
refractory aggressive non-Hodgkin lymphoma (NHL)
- Abstract # CT019
- Presenter: Frederick L. Locke, M.D.,
Moffitt Cancer Center, Tampa, FL
- Session: Immuno-oncology Biomarkers in
Clinical Trials Plenary Session
- Sunday, April 2, 2017: 4:05-4:14 PM
EDT; Hall D-E, Level 2
Immune signatures of cytokine release syndrome and neurologic
events in a multicenter registrational trial (ZUMA-1) in subjects
with refractory diffuse large B cell lymphoma treated with
axicabtagene ciloleucel (KTE-C19)
- Abstract # CT020
- Presenter: Frederick L. Locke, M.D.,
Moffitt Cancer Center, Tampa, FL
- Session: Immuno-oncology Biomarkers in
Clinical Trials Plenary Session
- Sunday, April 2, 2017: 4:14-4:24 PM
EDT; Hall D-E, Level 2
Polyfunctional anti-CD19 CAR T cells determined by
single-cell multiplex proteomics associated with clinical activity
in patients with advanced non-Hodgkin’s lymphoma
- Abstract # 2990
- Presenter: John M. Rossi, M.S., Kite
Pharma
- Session: Clinical Research, Clinical
Biomarkers
- Monday, April 3, 2017: 4:05-4:20 PM
EDT; Room 151, Level 1
Development of KITE-585: A fully human BCMA CAR T-cell
therapy for the treatment of multiple myeloma
- Abstract # 4979
- Presenter: Gregor B. Adams, Ph.D., Kite
Pharma
- Session: Immunology: Adoptive Cellular
Therapy for Cancer
- Tuesday, April 4, 2017: 3:35-3:50 PM
EDT; Ballroom A-B, Level 3
Poster Presentations
Selectivity and specificity of engineered T cells expressing
KITE-585, a chimeric antigen receptor targeting B-cell maturation
antigen (BCMA)
- Abstract # 2135
- Presenter: Tassja Spindler, Kite
Pharma
- Session: Experimental and Molecular
therapeutics: New Targets 2
- Monday, April 3, 2017: 1:00-5:00 PM
EDT; Halls A-C, Poster Section 6
About axicabtagene ciloleucel
Kite’s lead product candidate, axicabtagene ciloleucel, is an
investigational therapy in which a patient’s T cells are engineered
to express a chimeric antigen receptor (CAR) to target the antigen
CD19, a protein expressed on the cell surface of B-cell lymphomas
and leukemias, and redirect the T cells to kill cancer cells.
Axicabtagene ciloleucel has been granted Breakthrough Therapy
Designation status for diffuse large B-cell lymphoma (DLBCL),
transformed follicular lymphoma (TFL), and primary mediastinal
B-cell lymphoma (PMBCL) by the U.S. Food and Drug
Administration (FDA) and Priority Medicines (PRIME) regulatory
support for DLBCL in the EU.
About KITE-585
KITE-585 is an investigational therapy in which a patient’s T
cells are engineered to express a chimeric antigen receptor (CAR)
to target the B cell maturation antigen (BCMA), a protein expressed
on the cell surface of multiple myelomas (MM), and redirect the T
cells to kill cancer cells. In 2016, there were an estimated 30,330
new cases of MM and 12,650 disease related deaths in the US1.
Current treatments, including multi-therapy combinations, require
chronic care and most patients will eventually relapse2. Kite
expects to file an Investigational New Drug Application (IND) for
KITE-585 in 2017.
About Kite
Kite is a biopharmaceutical company engaged in the development
of innovative cancer immunotherapies with a goal of providing
rapid, long-term durable response and eliminating the burden of
chronic care. The company is focused on chimeric antigen receptor
(CAR) and T cell receptor (TCR) engineered cell therapies designed
to empower the immune system’s ability to recognize and kill
tumors. Kite is based in Santa Monica, CA. For more
information on Kite, please visit www.kitepharma.com. Sign up
to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the promise of anti-CD19 CAR T cell therapy to
transform treatment of B-cell malignancies and the ability to
accelerate the development of Kite’s pipeline candidates such as
KITE-585 into the clinic later this year. Various factors may cause
differences between Kite’s expectations and actual results as
discussed in greater detail in Kite’s filings with the Securities
and Exchange Commission, including without limitation in its Form
10-K for the year ended December 31, 2016. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Kite assumes no obligation to update
the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
1 SEER
2 NCCN and Rajkumar and Kumar, Mayo Clin Proc, 2016
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005439/en/
Kite Pharma, Inc.Christine CassianoSVP, Corporate Communications
& Investor Relationsccassiano@kitepharma.comorGreg MannVP,
Investor Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2023 to Apr 2024